Susquehanna Fundamental Investments’s PharmaCyte Biotech PMCB Stock Holding History

Susquehanna Fundamental Investments’s Portfolio PMCB Stock Details PMCB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$80K	Sell	34,805 -10,139	-23%	-$22.5K	﹤0.01%	1473
2021 Q4	$112K	Sell	44,944 -4,756	-10%	-$13.1K	﹤0.01%	1327
2021 Q3	$158K	Buy	+49,700	New	+$175K	﹤0.01%	1571

Other funds holding PMCB

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EPM

Equitec Proprietary Markets Chicago, Illinois $559M AUM 230.29% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ayrton Capital Westport, Connecticut $14.7M AUM 12.82% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

FIA

FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Susquehanna Fundamental Investments's PMCB Position: Q1 2022 in Review

Susquehanna Fundamental Investments reduced its PharmaCyte Biotech (PMCB) stake by 23% in Q1 2022, selling an estimated $22.5K and leaving 34,805 shares worth $80K. The position accounts for ﹤0.01% of the portfolio, ranked #1473.

Susquehanna Fundamental Investments first reported a position in PMCB in Q3 2021 and has held it in 3 quarters since. The position peaked at $158K in Q3 2021. 25 funds tracked by Wall St. Rank hold PMCB as of Q1 2022.

Susquehanna Fundamental Investments held 34,805 shares of PharmaCyte Biotech worth $80K as of Q1 2022.
Susquehanna Fundamental Investments sold 10,139 PharmaCyte Biotech shares in Q1 2022, an estimated $22.5K.
PharmaCyte Biotech made up ﹤0.01% of Susquehanna Fundamental Investments's portfolio in Q1 2022, its #1473 holding.
Susquehanna Fundamental Investments first reported a position in PharmaCyte Biotech in Q3 2021 and has held it in 3 quarters since.
Susquehanna Fundamental Investments's PharmaCyte Biotech position peaked at $158K in Q3 2021.
25 funds tracked by Wall St. Rank held PharmaCyte Biotech as of Q1 2022.

Based on Susquehanna Fundamental Investments's 13F filing for Q1 2022, filed 16 May 2022.